Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.

ABSTRACT:

Importance

Accurate, accessible predictions of posttreatment hearing loss for patients with head and neck cancer prior to the initiation of treatment are a necessary part of informed patient decision-making.

Objective

To develop a prediction model for postradiotherapy and/or post-cisplatin chemotherapy hearing loss for patients with head and neck cancer.

Design, setting, and participants

A retrospective cohort study was conducted at a tertiary academic medical center among 242 patients (482 ears) with head and neck cancer who were treated with radiotherapy and/or cisplatin from October 1, 2014, to July 31, 2018, and had follow-up audiometric data available.

Exposures

Radiotherapy and cisplatin chemotherapy.

Main outcomes and measures

Patient hearing leve

SUBMITTER: Schuette A 

PROVIDER: S-EPMC6902235 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature